Core Viewpoint - Neurothera Labs Inc. has received a U.S. patent for its proprietary combination of antimicrobials and cannabinoids aimed at enhancing the efficacy of existing antibiotics against resistant bacterial strains [1][2]. Company Summary - Neurothera Labs Inc. is a clinical-stage biotech company focused on developing innovative therapeutics, particularly in the area of antimicrobial resistance [10]. - The company is a majority-owned subsidiary of SciSparc Ltd. [1]. Technology and Innovation - The patented technology combines established antibiotics with cannabinoids like THC and CBD, demonstrating enhanced antimicrobial activity against resistant pathogens such as MRSA in preclinical studies [3][5]. - The platform aims to restore the effectiveness of antibiotics that are ineffective as monotherapy against resistant Gram-positive pathogens [3]. Market Context - The global antibiotics market is projected to reach approximately $58 billion in 2026, driven by the rising challenge of antimicrobial resistance [6]. - The emergence of resistant bacterial strains, particularly MRSA, has led to a significant increase in healthcare-acquired infections, with a reported 30% rise in the U.S. [6]. Antimicrobial Resistance Challenge - Prolonged antibiotic use has resulted in the emergence of resistant strains, with MRSA causing approximately 130,000 deaths worldwide in 2021, more than double the 57,000 deaths in 2019 [4]. - Overall, bacterial antimicrobial resistance caused 1.14 million deaths and was associated with 4.71 million deaths globally in 2021 [4]. Industry Dynamics - Pharmaceutical companies are increasingly reluctant to develop new antibiotics due to high costs and lengthy development timelines, leading to a gap in innovation as major firms exit the field [8][9]. - The need for innovative solutions that enhance the efficacy of existing antibiotics while improving safety is critical in the current landscape of antimicrobial resistance [6][7].

Core Viewpoint - SciSparc Ltd. announced a definitive agreement to acquire a portfolio of medical endoscopy patents, aiming to expand its presence in the medical device sector and accelerate commercialization plans [1][2][3]. Group 1: Acquisition Details - The acquisition includes patents, trademarks, and related rights associated with endoscopic systems and medical cameras, specifically the MUSE endoscopic system designed for minimally invasive procedures [2]. - The company plans to issue ordinary shares to the seller at closing, which will represent approximately 19.99% of the company's outstanding stock [4]. - SciSparc may opt to issue pre-funded warrants instead of some shares at its discretion [5]. Group 2: Commercial Strategy - SciSparc intends to commercialize the acquired technologies immediately after the deal closes, aiming to replicate existing successful distribution models [4]. - The company plans to leverage licensing and regional partnerships to expand its market reach in North America, Europe, and Latin America [4]. Group 3: Closing Conditions and Market Outlook - The acquisition is subject to customary conditions, including regulatory approvals, with an expected closing date by March 8, 2026 [6]. - A market research report indicates growth in the global GERD device market, driven by demand for innovative endoscopy systems, which may help SciSparc extend its reach into new medical segments alongside its pharmaceutical initiatives [6]. Group 4: Stock Performance - Following the announcement, SciSparc shares were trading lower by 12.07% to $1.27 [7].

Core Viewpoint - SciSparc Ltd. has announced a definitive agreement to acquire a treasury of patents, trademarks, and intellectual property rights related to innovative endoscopic systems and medical cameras from Xylo Technologies Ltd. [1] Group 1: Acquisition Details - The acquisition includes the MUSE system and other related technologies [1] - SciSparc will issue common shares to Xylo as consideration for the acquired assets [1] Group 2: Commercialization and Market Impact - Upon closing the deal, SciSparc plans to commence commercialization of the patented technologies immediately [2] - This move is expected to enhance rapid market penetration and revenue generation for the company [2] - Following the announcement, SciSparc's stock price increased by 21.3 percent, reaching $1.76 on the Nasdaq during pre-market hours [2]

Core Points - Neurothera Labs Inc. held its annual and special meeting of shareholders on January 8, 2026, where key decisions were made regarding the company's governance and future plans [1] Group 1: Shareholder Decisions - All nominee directors listed in the management information circular dated December 4, 2025, were elected as directors [2] - Shareholders voted to appoint Dale Matheson Carr-Hilton Labonte LLP as auditors for the upcoming year and authorized the directors to fix their remuneration [2] - A consolidation of common shares was authorized, allowing for a potential consolidation of one post-consolidation share for up to one hundred pre-consolidation shares, subject to the directors' discretion and market conditions [3] - The adoption of a 20% fixed equity incentive plan was approved, pending final approval from the TSX Venture Exchange [4] Group 2: Company Overview - Neurothera Labs Inc. is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations [5]

Company Performance - Ulta Beauty, Inc. reported quarterly earnings of $5.14 per share, surpassing the analyst estimate of $4.54 by 13.27% [1] - The company's quarterly revenue reached $2.858 billion, exceeding the Street estimate of $2.72 billion and showing an increase from $2.53 billion in the same period last year [1] Market Reaction - Shares of Ulta Beauty rose 5.7% to $564.16 in pre-market trading following the earnings report [2]

Core Viewpoint - SciSparc Ltd. is strategically expanding its operations by acquiring endoscopy intellectual property from Xylo Technologies Ltd., moving beyond its core neuroscience pipeline into medical device commercialization [1]. Strategic IP Acquisition - SciSparc has signed a binding term sheet to acquire a portfolio of patents, trademarks, and know-how related to advanced endoscopic imaging systems, focusing on the MUSE platform, a single-use device for transoral fundoplication procedures aimed at treating gastroesophageal reflux disease (GERD) [2]. Expansion into Procedural Technology - Through its majority-held subsidiary NeuroThera Labs Inc., SciSparc has primarily focused on clinical-stage therapies. The acquisition broadens its exposure into procedural technology for gastrointestinal treatment markets [3]. MUSE Commercial Potential - The MUSE device facilitates minimally invasive treatment for GERD patients. SciSparc intends to leverage Xylo's previous commercialization success in Greater China to penetrate North America, Europe, and Latin America. Xylo had previously secured a licensing deal in 2019 with a Shanghai-based distributor, receiving $3 million upfront, which SciSparc plans to replicate through exclusive regional partnerships [4]. Share-Based Consideration Structure - Under the terms of the acquisition, SciSparc will issue equity equal to 19.99% of its outstanding shares upon closing, with the option to substitute part or all of that with pre-funded warrants. This acquisition grants SciSparc direct ownership of the technology and commercialization rights, potentially supporting future licensing revenue and enhancing its diversification strategy [5]. Price Action - Following the announcement, SciSparc shares increased by 29.10%, reaching $3.15, while the stock is near its 52-week low of $1.75 [6].

Core Insights - Premarket trading is showing notable activity with significant price movements indicating potential trading opportunities before the market opens [1] Premarket Gainers - Chijet Motor Company, Inc. (CJET) is up 40% at $2.67 - JX Luxventure Group Inc. (JXG) is up 19% at $4.12 - Inspire Medical Systems, Inc. (INSP) is up 15% at $103.50 - Epsium Enterprise Limited (EPSM) is up 15% at $4.14 - Oscar Health, Inc. (OSCR) is up 12% at $15.13 - Green Dot Corporation (GDOT) is up 11% at $13.21 - Butterfly Network, Inc. (BFLY) is up 6% at $2.82 - Cullinan Therapeutics, Inc. (CGEM) is up 5% at $10.00 - Vir Biotechnology, Inc. (VIR) is up 5% at $5.99 - Nvni Group Limited (NVNI) is up 5% at $3.17 [3] Premarket Losers - Clearside Biomedical, Inc. (CLSD) is down 69% at $0.82 - Twin Hospitality Group Inc. (TWNP) is down 20% at $2.84 - Shuttle Pharmaceuticals Holdings, Inc. (SHPH) is down 15% at $1.35 - Mobile-Network Solutions (MNDR) is down 12% at $4.16 - Waldencast plc (WALD) is down 10% at $2.75 - authID Inc. (AUID) is down 9% at $1.21 - EZGO Technologies Ltd. (EZGO) is down 6% at $1.98 - SciSparc Ltd. (SPRC) is down 5% at $2.34 - Twin Vee Powercats Co. (VEEE) is down 5% at $1.70 - Agape ATP Corporation (ATPC) is down 5% at $1.22 [4]

Core Insights - Neurothera Labs Inc. announced that Clearmind Medicine Inc. has filed an Israeli patent application for a combination therapy targeting depression, utilizing 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines like Palmitoylethanolamide (PEA) [1][2] - The collaboration between Neurothera and Clearmind aims to address the significant global issue of major depressive disorder, which affects over 280 million people and is a leading cause of disability [2] Company Overview - Neurothera Labs Inc. is a clinical-stage biotech company focused on developing innovative therapeutics for central nervous system disorders and other underserved health conditions through collaborations [4] Intellectual Property Development - The recent patent application expands the joint intellectual property portfolio, which now includes 13 patents related to MEAI and N-Acylethanolamines for various conditions, including depression, alcohol use disorder, cocaine addiction, and obesity [3]

Core Insights - Clearmind Medicine Inc. has filed a patent application in Israel for a combination therapy targeting depression, utilizing 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines like Palmitoylethanolamide (PEA) [1][2] - The collaboration with Neurothera Labs Inc. aims to address the significant global issue of major depressive disorder, which affects over 280 million people and is a leading cause of disability [2] - The CEO of Clearmind emphasized the importance of this patent application as a milestone in developing innovative treatments for mental health conditions, highlighting the lag in treatment innovation for depression [3] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to address under-treated health issues, including alcohol use disorder [4] - The company has an extensive intellectual property portfolio, currently consisting of 19 patent families and 31 granted patents, with plans to seek additional patents as warranted [5] Research and Development - The new patent filing expands Clearmind's intellectual property related to MEAI and N-Acylethanolamines, targeting various conditions such as alcohol use disorder, cocaine addiction, obesity, and depression [3] - Preclinical data supports the efficacy of MEAI in reducing addictive behaviors while maintaining normal reward pathways [3]

Core Viewpoint - N2OFF, Inc. has successfully completed the merger with MitoCareX Bio Ltd., expanding its portfolio into the biotech sector focused on cancer therapeutics [1][3]. Company Overview - N2OFF is a cleantech company primarily engaged in solar energy assets using the Ready to Build (RTB) business model, with investments in four solar projects across three EU countries [5]. - The company also controls approximately 98% of Save Foods Ltd., which specializes in post-harvest treatments for fruits and vegetables [6]. MitoCareX Overview - MitoCareX is a biotech firm dedicated to developing novel therapies for challenging cancers by targeting the mitochondrial SLC25 protein family [2]. - The company utilizes its proprietary algorithm, MITOLINE™, for 3D comparative modeling of mitochondrial proteins, aiding in the identification of anti-cancer small molecule therapeutics [2]. Merger Details - The acquisition of MitoCareX was finalized on October 20, 2025, with N2OFF purchasing ordinary shares for $700,000 and acquiring the remaining shares, making MitoCareX a wholly-owned subsidiary [3]. - The agreement stipulates that the sellers will receive 30% of N2OFF's financing proceeds, capped at $1.6 million, for five years, along with milestone-based issuances of up to 25% of N2OFF's common stock [3]. Market Potential - The Global Cancer Therapeutics and Biotherapeutics Market is projected to grow from $211.02 billion in 2025 to $378.62 billion by 2032, with a compound annual growth rate (CAGR) of 8.7% [2].